<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN"
                      "http://www.w3.org/TR/html4/strict.dtd">
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta name="generator" content="hypermail 2.1.5, see http://www.hypermail.org/">
<title>Extropians: RE: PD</title>
<meta name="Author" content="Lee Corbin (lcorbin@tsoft.com)">
<meta name="Subject" content="RE: PD">
<meta name="Date" content="2003-02-08">
<style type="text/css">
body {color: black; background: #ffffff}
h1.center {text-align: center}
div.center {text-align: center}
</style>
</head>
<body>
<h1>RE: PD</h1>
<!-- received="Sat Feb  8 02:48:15 2003" -->
<!-- isoreceived="20030208094815" -->
<!-- sent="Sat, 8 Feb 2003 01:54:08 -0800" -->
<!-- isosent="20030208095408" -->
<!-- name="Lee Corbin" -->
<!-- email="lcorbin@tsoft.com" -->
<!-- subject="RE: PD" -->
<!-- id="JEEOJKGAIKFKEHJONHMPIENMEBAA.lcorbin@tsoft.com" -->
<!-- charset="iso-8859-1" -->
<!-- inreplyto="BMEDJIBJGLNDOOANGIDLEELACJAA.rms2g@virginia.edu" -->
<!-- expires="-1" -->
<p>
<strong>From:</strong> Lee Corbin (<a href="mailto:lcorbin@tsoft.com?Subject=RE:%20PD"><em>lcorbin@tsoft.com</em></a>)<br>
<strong>Date:</strong> Sat Feb 08 2003 - 02:54:08 MST
</p>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="2307.html">Alex Ramonsky: "Re: Performance enhancement with selegiline"</a>
<ul>
<li><strong>Previous message:</strong> <a href="2305.html">Lee Corbin: "RE: Anniversary of Roe v. Wade"</a>
<li><strong>In reply to:</strong> <a href="2282.html">Rafal Smigrodzki: "PD"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="2311.html">Anders Sandberg: "Re: PD"</a>
<li><strong>Reply:</strong> <a href="2311.html">Anders Sandberg: "Re: PD"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#2306">[ date ]</a>
<a href="index.html#2306">[ thread ]</a>
<a href="subject.html#2306">[ subject ]</a>
<a href="author.html#2306">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<hr>
<!-- body="start" -->
<p>
Rafal writes
<br>
<p><em>&gt; Ian Reilly wrote:
</em><br>
<em>&gt; &gt; REGARDING PARKINSONS:
</em><br>
<em>&gt; &gt;     Some of you may be interested to know that the Swedes treated a
</em><br>
<em>&gt; &gt; drug induced severe Parkinson's type disorder with embryonic stem
</em><br>
<em>&gt; &gt; cells. The treatment was apparently successful, albeit extremely
</em><br>
<em>&gt; &gt; expensive. It involved injecting the dopamine producing stem cells
</em><br>
<em>&gt; &gt; into the region of the brain that is damaged by PD. The experimental
</em><br>
<em>&gt; &gt; treatment was done on some people from California. There was also a
</em><br>
<em>&gt; &gt; bit on the program about the severity of the side effects of Levadopa
</em><br>
<em>&gt; &gt; - apparently it is very nasty stuff - debilitating side effects are
</em><br>
<em>&gt; &gt; inevitable if the patient continues to take it.
</em><br>
<em>&gt; 
</em><br>
<em>&gt; ### You might want to peruse some articles in &quot;Neurology&quot; over the past two
</em><br>
<em>&gt; years, showing that stem cell implants are as yet a highly immature
</em><br>
<em>&gt; technology, suitable strictly for research purposes due to major surgical
</em><br>
<em>&gt; and other risks, as well as lack of clear evidence of sustained efficacy.
</em><br>
<p>Well, don't you think that the individual patient, his or her family,
<br>
and their familial medical practitioners should have a say in the
<br>
matter?  In some individual condition, it might be the best option
<br>
to adopt a treatment that has very little chance of success.  So
<br>
who should decide?
<br>
<p>Why, ---wait--- don't tell me!  I know!  It must be left to
<br>
Professional Bodies hundreds or thousands of miles away who
<br>
are not familiar with the particular distress of a particular
<br>
condition, but whose wisdom so exceeds that of the individuals
<br>
directly involved, that the matter simply cannot be left in
<br>
the ignorant and incompetent hands of the locals!  Right?
<br>
<p>Thank goodness the Swedes or some other researchers out of 
<br>
reach are not required to follow the central directives of
<br>
our wonderful American FDA.
<br>
<p>Lee
<br>
<!-- body="end" -->
<hr>
<ul>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="2307.html">Alex Ramonsky: "Re: Performance enhancement with selegiline"</a>
<li><strong>Previous message:</strong> <a href="2305.html">Lee Corbin: "RE: Anniversary of Roe v. Wade"</a>
<li><strong>In reply to:</strong> <a href="2282.html">Rafal Smigrodzki: "PD"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="2311.html">Anders Sandberg: "Re: PD"</a>
<li><strong>Reply:</strong> <a href="2311.html">Anders Sandberg: "Re: PD"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#2306">[ date ]</a>
<a href="index.html#2306">[ thread ]</a>
<a href="subject.html#2306">[ subject ]</a>
<a href="author.html#2306">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<!-- trailer="footer" -->
<hr>
<p><small><em>
This archive was generated by <a href="http://www.hypermail.org/">hypermail 2.1.5</a> 
: Sat Feb 08 2003 - 02:50:23 MST
</em></small></p>
</body>
</html>
